johnsonii MH 68 and L. salivarius subsp. salicinius AP-32 effectively suppressed H. pylori viability, and decreased the level of gastritis [80]. A meta-analysis of 10 clinical

trials was carried out on this hot topic in the past year and obtained by ITT analysis a pooled odds ratio of 2.066 in favor of the probiotics supplementation group vs the group without probiotics. In addition, a pooled odds ratio of 0.305 was calculated for the incidence of total side effects in the probiotics Pexidartinib supplier supplementation group. This suggests beneficial effects of probiotics both on efficacy and tolerance [81]. A recurrence risk for H. pylori infection of 11.5% was observed in a multicentre Latin American study. Recurrence was significantly associated with study site, nonadherence to initial therapy and children in the household [82]. This is a considerably higher recurrence rate than the previously documented. There have been many and diverse studies pertaining to H. pylori eradication treatment in the published literature over the last 12 months, often with conflicting outcomes. Cure rates for standard triple therapy remain acceptable in quite a few settings nowadays, with evolving novel triple therapies being added to our armamentarium. Regarding newer nonbismuth quadruple regimens, there is a trend of superiority emerging for the concomitant therapy over the sequential regimen, although this may imply greater financial

costs and probably higher ecological impact. Selumetinib Further research is warranted with the hybrid therapy, that is, combining sequential and concomitant therapy. Bismuth remains a viable option, particularly in second-line

treatment, where available. Levofloxacin-based therapies appear to be useful and versatile as part of different antibiotic combinations and in first-, second-, and third-line therapies. The emerging problem of quinolone resistance remains worrying, but there is some hope selleck that newer generation quinolones may partially overcome this issue, especially sitafloxacin, moxifloxacin, or gemifloxacin. Some promising works have been reported for rescue therapy using individualized therapies upon antimicrobial resistance information. Probiotic therapy, especially with Lactobacillus sp., appears to have a clear effect in terms of reducing side effects and probably improving compliance, but insufficient data exists as of yet to conclude that their use improves eradication rates. In some geographical areas, recurrence of H. pylori infection is more common than had previously been thought and this, coupled with the poor rates of compliance to testing to ensure eradication has been achieved, is a cause of concern. Competing interests: the authors have no competing interests. “
“The resistance of Helicobacter pylori (H. pylori) to antibiotics is increasing worldwide, lowering its efficacy in current eradication therapies. This study evaluated H.